These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 2879443)
21. [Are all antihypertensive drugs renoprotective?]. Wolf S; Risler T Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950 [TBL] [Abstract][Full Text] [Related]
22. Effects of calcium entry blockers on renin-angiotensin-aldosterone system, renal function and hemodynamics, salt and water excretion and body fluid composition. Bauer JH; Sunderrajan S; Reams G Am J Cardiol; 1985 Dec; 56(16):62H-67H. PubMed ID: 2933950 [TBL] [Abstract][Full Text] [Related]
23. Influence of antihypertensive therapy on renal function. Frei U; Schindler R; Koch KM Clin Investig; 1992; 70 Suppl 1():S120-6. PubMed ID: 1591504 [TBL] [Abstract][Full Text] [Related]
24. Renin system activity as a determinant of response to treatment in hypertension and heart failure. Cody RJ; Laragh JH; Case DB; Atlas SA Hypertension; 1983; 5(5 Pt 2):III36-42. PubMed ID: 6354936 [TBL] [Abstract][Full Text] [Related]
25. Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients. Bühler FR; Bolli P; Kiowski W; Erne P; Hulthén UL; Block LH Am J Med; 1984 Aug; 77(2A):36-42. PubMed ID: 6148011 [TBL] [Abstract][Full Text] [Related]
29. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention. Talbert RL J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609 [TBL] [Abstract][Full Text] [Related]
33. Renal protection in essential hypertension: how do angiotensin-converting enzyme inhibitors compare with calcium antagonists? Bauer JH; Reams GP J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S80-7. PubMed ID: 16989071 [TBL] [Abstract][Full Text] [Related]
34. Calcium entry blockers: antihypertensive and natriuretic effects in experimental animals. Nagao T; Yamaguchi I; Narita H; Nakajima H Am J Cardiol; 1985 Dec; 56(16):56H-61H. PubMed ID: 3878075 [TBL] [Abstract][Full Text] [Related]
35. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154 [TBL] [Abstract][Full Text] [Related]
36. Are there benefits to specific antihypertensive drug therapy? Cushman WC Am J Hypertens; 2003 Nov; 16(11 Pt 2):31S-35S. PubMed ID: 14625158 [TBL] [Abstract][Full Text] [Related]
37. [Antihypertensive drugs for therapy of hypertension due to long-term hemodialysis]. Kikawada R; Tsuyusaki T Nihon Rinsho; 1991 Dec; 49 Suppl():702-8. PubMed ID: 1687286 [No Abstract] [Full Text] [Related]
38. Angiotensin converting enzyme inhibition and the kidney. Hollenberg NK Curr Opin Cardiol; 1988; 3(Suppl 1):S19-29. PubMed ID: 11538849 [TBL] [Abstract][Full Text] [Related]
39. [New central agents in the treatment of arterial hypertension]. Robles NR An Med Interna; 1999 Oct; 16(10):495-7. PubMed ID: 10603665 [No Abstract] [Full Text] [Related]
40. Calcium-entry blocking agents in the treatment of systemic hypertension. Robinson BF Am J Cardiol; 1985 Jan; 55(3):102B-106B. PubMed ID: 2857516 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]